HALIFAX,
July 11, 2014 /CNW/ - MedMira, Inc.
(MedMira) (TSXV: MIR) announced today that Markus Meile has been appointed as the Company's
Chief Financial Officer. Effective immediately, Mr. Meile
replaces Jelle Kuypers who has
chosen to depart the Company. Mr. Meile's proficiency in
international finance, in addition to his experience in the medical
device industry, makes him a valued member of the Company's
executive leadership team as it drives MedMira's strategic
initiatives forward. Mr. Kuypers will assist with the
transfer of the Company's financial leadership and day-to-day
functions to Mr. Meile and his team during a defined transition
period.
Mr. Meile has served as a member of MedMira's
Board of Directors since 2010, was previously a member of its Audit
Committee and, most recently, led the Company's business
development activities as Senior Director, International
Markets. Effectively immediately, Mr. Meile will step down
from the Board to move into his new role as Chief Financial
Officer.
"On behalf of the Board and the management team,
I would like to thank Mr. Kuypers for his contributions to MedMira
and the support provided to the Company during this transition
period. Mr. Kuypers has helped MedMira move to an enhanced
financial foundation upon which our future success will be built,"
said Hermes Chan, CEO, MedMira
Inc.
Prior to joining MedMira, Mr. Meile worked with
a number of financial institutions in Switzerland, England, and Hong
Kong. Mr. Meile holds a BSc from Royal Holloway University
of London and has studied business
management, strategic planning, investment and accounting at
business school in Zurich.
Previously, Mr. Meile worked in the medical device industry in
Africa, Asia Pacific, and Europe. Mr. Meile will combine his financial
expertise with his broad range of international business knowledge
to build financial and corporate strategies supporting MedMira's
continuing growth and increasing shareholder value.
Mr. Meile's appointment as MedMira's Chief
Financial Officer is subject to final approval of the TSX Venture
Exchange.
About MedMira
MedMira is a leading developer and manufacturer
of vertical flow rapid diagnostics. The Company's tests provide
hospitals, labs, clinics and individuals with instant diagnosis for
diseases such as HIV and hepatitis C in just three easy steps. The
Company's tests are sold under the Revealâ, Multiplo™
and Miriad™ brands in global markets. Based on its patented Rapid
Vertical Flow Technology™, MedMira's rapid HIV test is the first
one in the world to achieve regulatory approvals in Canada, the United
States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova
Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking
statements, which involve risk and uncertainties and reflect the
Company's current expectation regarding future events including
statements regarding possible approval and launch of new products,
future growth, and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from
time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE MedMira Inc.